Laurence Lacaze

Laurence Lacaze

Auto-generated profile, based on publicly available information

Laurence Lacaze

Department of General Surgery, Mantes-la-Jolie Hospital, Mantes-la-Jolie, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Clinical Nutrition
Verified
Journal Article
Open access
SBStephan C. Bischoff
Stephan C. Bischoff
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
MCMarjo J.E. Campmans-Kuijpers
Marjo J.E. Campmans-Kuijpers
VCVincenzo Cardinale
Vincenzo Cardinale
CCCristina Cuerda
Cristina Cuerda
Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence. The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity. The present guideline was developed according to the standard operating procedure for ESPEN guidelines, following the Scottish Intercollegiate Guidelines Network (SIGN) grading system (A, B, 0, and good practice point (GPP)). The procedure included an online voting (Delphi) and a final consensus conference. In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity - including sarcopenic obesity - is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician. The present guideline offers for the first time evidence-based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.

12 August 2022 in United European Gastroenterology Journal
Verified
Journal Article
Open access
SBStephan C. Bischoff
Stephan C. Bischoff
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
MCMarjo J.E. Campmans-Kuijpers
Marjo J.E. Campmans-Kuijpers
VCVincenzo Cardinale
Vincenzo Cardinale
CCCristina Cuerda
Cristina Cuerda
Background: Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence.Objective: The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity.Methods: The present guideline was developed according to the standard operating procedure for European Society for Clinical Nutrition and Metabolism guidelines, following the Scottish Intercollegiate Guidelines Network grading system (A, B, 0, and good practice point [GPP]). The procedure included an online voting (Delphi) and a final consensus conference.Results: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity – including sarcopenic obesity – is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician.Conclusion: The present guideline offers for the first time evidence‐based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.

10 April 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
SBStephan C. Bischoff
Stephan C. Bischoff
JOJohann Ockenga
Johann Ockenga
AEAhad Eshraghian
Ahad Eshraghian
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
CCCristina Cuerda
Cristina Cuerda

1 September 2011 in The Lancet
Verified
Journal Article
Closed access
VBValery Brunel
Valery Brunel
BCBruno Cauliez
Bruno Cauliez
LLLaurence Lacaze
Laurence Lacaze
GRGhassan Riachi
Ghassan Riachi
GGGilles Gargala
Gilles Gargala
MSMichel Scotté
Michel Scotté

1 November 2012 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
LLL. Lacaze
L. Lacaze
MSM. Scotté
M. Scotté

2 September 2022 in Nutrition and Cancer
Verified
Journal Article
Closed access
LLLaurence Lacaze
Laurence Lacaze
DBDamien Bergeat
Damien Bergeat
CRChloé Rousseau
Chloé Rousseau
LSLaurent Sulpice
Laurent Sulpice
DVDavid Val-Laillet
David Val-Laillet
KBKarim Boudjema
Karim Boudjema
The impact of body composition (BC) on the prognosis of resected intrahepatic cholangiocarcinoma (ICC) has been poorly studied. Aims: i) to evaluate the prevalence of low muscle mass (MM) in patients; ii) to assess the impact of BC on patient overall survival (OS) and disease-free survival (DFS), and iii) on the incidence of postoperative complications. All consecutive patients who underwent liver resection for ICC between 2004 and 2016 and who had preoperative CT scans were included. Ninety-three patients were included. Sixty percent (55/91) had low total MM. On multivariable analysis, high visceral fat (HR 2.48, CI95% [1.63; 3.77], p < 0.0001), nodules >1 (HR 3.15 [1.67; 5.93], p = 0.0004), involvement adjacent organ (HR 6.67 [1.88; 23.69], p = 0.003), and postoperative sepsis (HR 3.04 [1.54; 5.99], p = 0.0013) were independently associated with OS. High visceral fat (HR 2.10 [1.31; 3.38], p = 0.002], nodules >1 (HR 3.01, [1.49; 6.10], p = 0.002), postoperative sepsis (HR 5.16 [2.24; 11.89], p = 0.0001), ASA score (p = 0.02) and perineural invasion (HR 3.30 [1.62; 6.76], p = 0.001) were independently associated with lower DFS. Conclusion: 60% of ICC patients had low MM before surgery. High visceral fat, but not muscle mass, was an independent prognostic factor for poor OS and DFS in European patients with resected ICC.